학술논문
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
Document Type
Academic Journal
Author
Meidhof, Simone; Brabletz, Simone; Lehmann, Waltraut; Preca, Bogdan-Tiberius; Mock, Kerstin; Ruh, Manuel; Schüler, Julia; Berthold, Maria; Weber, Anika; Burk, Ulrike; Lübbert, Michael; Puhr, Martin; Culig, Zoran; Wellner, Ulrich; Keck, Tobias; Bronsert, Peter; Küsters, Simon; Hopt, Ulrich T; Stemmler, Marc P; Brabletz, Thomas
Source
Embo Molecular Medicine. Jun 01, 2015 7(6):831-847
Subject
Language
English
ISSN
1757-4676
Abstract
ABSTRACT: SYNOPSIS: (Figure is included in full-text article.)Therapy resistance is a major problem in cancer medicine. Based on the identification of novel mediators of ZEB1-associated therapy resistance, the HDAC inhibitor mocetinostat is found to efficiently restore drug sensitivity in aggressive cancer cells.(Figure is included in full-text article.)